MS is associated with multiple genetic and environmental risk factors. Some environmental factors have been extensively studied, including vitamin D levels and smoking, but not air pollution. Airborne PM is a complex mixture of solids and aerosols. PM10 includes particles with a diameter of 10 μm or less, PM2.5 have a diameter of 2.5 μm or less that can penetrate even further into the lungs.
The researchers identified 927 MS patients resident in the province of Pavia (547,251 inhabitants) in Lombardy, Italy. They gathered spatial emission data for PM2.5 concentrations in winter, when PM concentrations peak. Municipalities were stratified into 3 groups by tertiles according to PM2.5 concentrations.
The overall MS prevalence in Pavia was 169.4 per 100,000 inhabitants, compared to 16 per 100,000 in 1974. In 2 of the 3 groups of municipalities, air pollution levels were above the European Commission threshold of 25 µg/m3. In the 2 groups with high air pollution levels, the risk of MS was 29% higher than in the third group with lower air pollution levels, which is a significant difference. The Bayesian map showed consistent high-risk clusters with an excess number of MS cases. The authors hope that this will encourage analytical studies in high-risk areas to analyse multiple environmental factors related to the uneven distribution of MS.
- Bergamaschi RGE, et al. Abstract EPR1151, EAN 2020.
Posted on
Previous Article
« Small fibre pathology as biomarker for fibromyalgia Next Article
Fampridine treatment results in routine clinical practice »
« Small fibre pathology as biomarker for fibromyalgia Next Article
Fampridine treatment results in routine clinical practice »
Table of Contents: EAN 2020
Featured articles
Alzheimer's Disease and Other Dementias
Non-Alzheimer’s disease pathophysiology in the elderly
Novel genetic association with resistance to ERC tau deposition
Diastolic dysfunction novel risk factor for cognitive impairment
Epilepsy
Avoidable epilepsy-related mortality remains high
How genetic testing can contribute to epilepsy management
Cenobamate effective in focal epilepsy
Sustained seizure reductions with cannabidiol for Lennox-Gastaut syndrome
Prevalence of autoantibodies in epilepsy almost 10%
Parkinson's Disease
White matter matters in Parkinson’s disease
Sleep disorders mark PD progression
Directional DBS superior to omnidirectional DBS
Stroke
Benefits of statins to prevent stroke outweigh risks
Extubation after thrombectomy: the sooner, the better
Thrombus location and length predictors of early neurological deterioration
Endovascular treatment in large vessel occlusion stroke patients treated with OAC
Early edoxaban may be safe after cardioembolic stroke
Headache and Pain
Small fibre pathology as biomarker for fibromyalgia
Migraine as a cyclical functional disorder
Reassuring real-world safety profile of 3 CGRP inhibitors
Long-term cardiovascular safety of erenumab
Real-world data for erenumab in Germany
Eptinezumab in chronic migraine and medication-overuse headache
Fremanezumab tolerability in cardiovascular patients with migraine
Effects of galcanezumab on health-related quality of life
Multiple Sclerosis
Imaging to evaluate remyelination and neuroprotection
Serum NfL predicts long-term clinical outcomes in MS
Epstein-Barr virus-targeted T-cell immunotherapy for progressive MS
High NEDA rates after 2 years of ocrelizumab
Switching from natalizumab to moderate- versus high-efficacy DMT
Results of compounds in late stages of development
Alemtuzumab efficacy and safety data of over 9 years
Fampridine treatment results in routine clinical practice
Air pollution is a possible risk factor for MS
Neuromyelitis Optica Spectrum Disorder
Genetic association studies in NMOSD needed
Eculizumab in NMOSD: the PREVENT study
Long-term safety of satralizumab consistent with double-blind periods
Neuromuscular Disorders
Biomarkers predicting motor function in SMA
Sustained benefits of avalglucosidase alfa in late-onset Pompe disease
Efficacy and safety of rituximab in refractory MG corroborated
Related Articles
September 9, 2020
Prevalence of autoantibodies in epilepsy almost 10%
September 9, 2020
How genetic testing can contribute to epilepsy management

September 10, 2020
Imaging to evaluate remyelination and neuroprotection
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com